• Newbury Pharmaceuticals secured Swedish marketing authorization for Prukalopride Newbury 1 mg and 2 mg tablets for chronic constipation.
• The generic version of Resolor targets a Swedish market estimated at EUR 580,000 annually.
• No further country approvals are currently planned.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Newbury Pharmaceuticals AB published the original content used to generate this news brief on October 27, 2026, and is solely responsible for the information contained therein.